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PURPOSE: Platinum resistance in ovarian cancer (OC) is associated with epigenetic
modifications. Hypomethylating agents (HMAs) have been studied as carboplatin re-sensitizing
agents in OC. This randomized phase 2 trial compared guadecitabine, a second generation HMA,
and carboplatin (G+C) against second-line chemotherapy in women with measurable or detectable
platinum-resistant OC.
PATIENTS AND METHODS: Patients received either G+C (guadecitabine 30 mg/m2 SC oncedaily for 5 days and carboplatin) or treatment of choice (TC; topotecan, pegylated liposomal
doxorubicin, paclitaxel, or gemcitabine) in 28-day cycles until progression or unacceptable
toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were
RECIST v1.1 and CA-125 response rate, 6-month PFS, and overall survival (OS).

Author Manuscript

RESULTS: Of 100 patients treated, 51 received G+C and 49 received TC, of which 27 crossed
over to G+C. The study did not meet its primary endpoint as the median PFS was not statistically
different between arms (16.3 weeks vs 9.1 weeks in the G+C and TC groups, respectively; P =
0.07). However, the 6-month PFS rate was significantly higher in the G+C group (37% vs. 11% in
TC group; P = 0.003). The incidence of grade 3 or higher toxicity was similar in G+C and TC
groups (51% and 49%, respectively), with neutropenia and leukopenia being more frequent in the
G+C group.
CONCLUSIONS: Although this trial did not show superiority for PFS of G+C versus TC, the 6month PFS increased in G+C treated patients. Further refinement of this strategy should focus on
identification of predictive markers for patient selection.

INTRODUCTION
Author Manuscript

Advanced stage high-grade serous ovarian cancer (HGSOC), which is distinctively
associated with a p53 mutated signature, has a poor estimated five-year survival of 50% (1).
Although patients with HGSOC usually respond to initial platinum-based chemotherapy,
relapses occur in most, leading to the development of platinum-resistance and subsequent
death (2-3). Progression of HGSOC to a platinum-resistant state is caused by multiple
mechanisms, including aberrant DNA repair responses, alterations in efflux pump proteins,
and accumulated genomic and epigenomic modifications which impact the response of
cancer cells to DNA damage. Adaptive responses include increased DNA methylation and
modifications of histone marks (4-5), which cause transcriptional silencing of tumor
suppressor genes (TSGs) and other genes required for chemotherapy-induced cell death
(6-7)

Author Manuscript

Given preclinical data demonstrating that targeting DNA methylation to re-sensitize HGSOC
to platinum is possible (8-11), we hypothesized this approach would restore platinum
sensitivity in HGSOC patients (12,13). With early clinical studies demonstrating feasibility
of this strategy (13-16), we set out to determine whether targeting DNA methylation induces
clinically meaningful activity in platinum-resistant HGSOC by conducting a randomized
phase 2 trial. The objectives were to measure and compare clinical outcomes of a
combination regimen of the DNA methyltransferase inhibitor (DNMTI), guadecitabine, and
carboplatin, versus FDA-approved physician’s choice chemotherapy (liposomal doxorubicin,
Clin Cancer Res. Author manuscript; available in PMC 2020 September 01.
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weekly paclitaxel, topotecan, or gemcitabine). Guadecitabine is a dinucleotide linking
decitabine to guanosine via a phosphodiester bond. Guadecitabine is resistant to degradation
by cytidine deaminase and has a longer half-life compared to other DNMTIs. In a dosefinding phase I trial (17), therapeutic plasma levels of decitabine persisted beyond 8 hours.
This pharmacokinetic profile provides a longer window of exposure to the hypomethylating
agent (HMA), potentially exposing more cancer cells undergoing S-phase to the parent drug,
decitabine, and promoting hypomethylation. Guadecitabine was shown to exert anti-tumor
activity in OC xenografts as a single agent and in combination with carboplatin (11, 18, 19).

Author Manuscript

A recently reported phase 1 trial established the tolerable and biologically active dose of
guadecitabine in combination with carboplatin (17). Guadecitabine was tolerable at 30
mg/m2 SC daily for 5 days prior to carboplatin on Day 8 at an AUC of 4. Each cycle was 28
days and the regimen induced ~20% hypomethylation of long interspersed nuclear elements
(LINE-1) in peripheral blood mononuclear cells (PBMCs), indicating biological activity.
The phase 1 trial reported three patients with partial response (PR) and six patients with
stable disease (SD) longer than 3 months (17), providing the rationale for conducting this
randomized trial in women with platinum-resistant HGSOC. Here we report clinical
outcomes with G+C as compared to physician’s choice FDA-approved chemotherapy for
OC in this high-need patient population.

METHODS
Trial Design and Patient Population:

Author Manuscript
Author Manuscript

This was a multicenter, randomized, open-label phase 2 trial conducted at 20 centers in the
US, UK, and Canada. Eligible patients were ≥18 years old with platinum-resistant
histologically- or cytologically-confirmed recurrent high-grade serous, or grade 2-3
endometrioid, mixed cell or clear cell epithelial OC; primary peritoneal carcinoma (PPC); or
fallopian tube (FT) cancer. All patients were required to have received carboplatin and
taxanes. Platinum-resistance was defined as recurrence within 6 months of the last platinumcontaining regimen. Patients were required to have either measurable disease according to
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or detectable disease, defined
as baseline values of CA-125 at least twice the upper limit of normal and one of the
following: (i) ascites and/or pleural effusion attributed to tumor, or (ii) solid and/or cystic
abnormalities on radiographic imaging that do not meet RECIST definitions for target
lesions. Tumor biopsies, paracentesis, or thoracentesis were performed to recover tumor
cells and were required at baseline and on Cycle 2 Day 8, if clinically safe and feasible.
Eligible patients had acceptable organ function based on laboratory data, Eastern
Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 and were ≥3 weeks
from their last therapy. Exclusion criteria included carboplatin hypersensitivity, prior HMA
therapy, progression on platinum treatment, left ventricular ejection fraction <50%, grade 2
or greater peripheral neuropathy, known brain metastases, other malignancies, active
infections, or life-threatening illnesses. The trial was conducted in accordance with the
International Council for Harmonisation Good Clinical Practice guidelines and applicable
local regulatory requirements according to the Declaration of Helsinki. Local Institutional
Review Boards and Independent Ethics Committees reviewed and approved the protocol and
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the informed consent form. Patients provided written informed consent before enrollment.
The trial is registered on ClinicalTrials.gov as . Trial protocol and amendments are available
as Supplements 1 and 2, respectively.
Randomization, Trial Intervention and Clinical Outcomes:

Author Manuscript

Eligible subjects were randomly assigned (1:1) to receive a 28-day treatment cycle of either
a G+C combination treatment (guadecitabine 30 mg/m2 SC once-daily on Days 1–5 and
carboplatin IV AUC 4 on Day 8), or treatment choice (TC) of topotecan IV (3.5–4.0
mg/m2/wk administered on Days 1, 8 and 15), pegylated liposomal doxorubicin IV (PLD;
40–50 mg/m2 administered on Day 1), paclitaxel IV (60–80 mg/m2/wk administered on
Days 1, 8, 15 and 22), or gemcitabine IV (800–1000 mg/m2 administered on Days 1, 8 and
15); treatment choice in the TC arm was at the investigator’s discretion. Randomization was
stratified by number of prior chemotherapies and by treatment center using an unblinded
approach using a centralized web-based system. Concomitant medications and therapies
were allowed, as deemed necessary for supportive care and safety of subjects; administration
of other anti-cancer agents was not permitted. Treatment in both arms continued until
disease progression or unacceptable toxicity. If the investigator decided to stop carboplatin
treatment after 4 or more cycles, guadecitabine could be continued until progression or
initiation of an alternative anti-cancer treatment. Crossover from the TC arm to the G+C arm
was permitted after evidence of disease progression in the standard therapy arm.
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The primary endpoint was PFS. Secondary efficacy endpoints included objective response
rate (ORR: defined as complete response [CR] and partial response [PR] based on both
measurable and evaluable disease), PFS at 6 months, clinical benefit rate (CBR: defined as
CR+ PR + stable disease for at least 3 months), proportion of patients with CA-125
reduction of at least 50%, duration of response (DOR), and overall survival (OS); in subjects
crossing over from the TC to the G+C arm, ORR was measured. Response was assessed
using RECIST v1.1 for patients with measurable disease (20), and modified Rustin criteria
for patients with detectable disease according to CA-125 criteria (21-22). Tumor
measurements were obtained by CT or MRI at screening, after every 2 cycles for the first six
cycles, and every three months until progression.
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Safety was assessed by subject-reported and investigator-observed adverse event (AE)
recording, along with physical examination, 12-lead electrocardiograms, hematology,
chemistry, and urinalysis with each cycle. There was a 30-day (+5 day) safety visit after the
last treatment. AEs were graded by Common Terminology Criteria for Adverse Events
(CTCAE) v4.0. Treatment-emergent AEs (TEAEs) were defined as events that first occurred
or worsened after the first dose of trial drug given on the first day of the first treatment cycle
until 30 days after the last dose of treatment. Related serious AEs (SAEs) that occurred more
than 30 days after the last dose were also considered TEAEs; AEs occurring after the start of
an alternative anti-cancer treatment were not considered TEAEs. Patients lost to follow-up
were included in statistical analyses to the point of their last evaluation.
Exploratory pharmacodynamic endpoints included quantitative analysis of LINE-1
methylation in PBMCs and tumor DNA, and of selected gene promoters in tumor tissue.
Blood samples for methylation assays were collected weekly during Cycle 1 and on Day 1
Clin Cancer Res. Author manuscript; available in PMC 2020 September 01.
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and Day 8 thereafter. Global DNA methylation was evaluated by sodium bisulfite
pyrosequencing for LINE-1 CpGs using PyroMark Q24 as previously described (17).
Ascites, pleural fluid, or fresh tumor biopsies were obtained at screening and on Day 8 of
Cycle 2 for assessment of methylation of selected genes listed in the supplementary
information (Supplementary Table S1). DNA was extracted from tumor biopsies or ascites
using DNeasy Blood & Tissue Kit (Qiagen, Netherlands) and LINE-1 and specific gene
pyrosequencing was performed at EpigenDx Inc (Hopkinton, MA).
Statistical Design and Analyses:

Author Manuscript

It was estimated a sample size of ≥96 patients randomized 1:1 into two treatment arms
would provide approximately 80% power to detect a difference between the two PFS curves
(median PFS of 15 vs. 28 weeks for the TC and G+C arms) at 5% significance level using a
two-sided log-rank test, assuming uniform accrual of subjects over 12 months, a 24-month
trial duration and an exponential distribution of the PFS endpoint. PFS, OS, and 95%
confidence intervals (CIs) were evaluated using the Kaplan-Meier method. PFS and OS were
compared using the log-rank test, while ORR and CBR were compared using Fisher’s exact
test. Subjects still alive with no progression and those who withdrew were censored on the
date of the last adequate tumor, CA-125, or clinical progression assessment. Subjects
initiating subsequent anti-cancer therapy, including those who crossed over, were censored
accordingly, but prior to the initiation. Survival time was censored on the last date the
subject was known to be alive or lost to follow-up before reaching the event of death.
Efficacy and safety data for subjects who crossed over were tabulated separately once
guadecitabine was first administered. All analyses are descriptive and inferential statistical
tests and CIs were two-sided with alpha equal to 0.05 unless otherwise specified. The
database was locked for analysis on July 7, 2016 with mature PFS data; 97 of the 100 treated
patients progressed or did not survive and all patients discontinued protocol therapy at this
time (Figure 1). LINE-1 and gene-specific methylation level differences before and after G
+C treatment were determined using paired t-tests. SAS version 9.3 was used for all
statistical analyses.

Author Manuscript

RESULTS

Author Manuscript

One hundred and three patients with HGSOC, FT cancer, or PPC were enrolled and
randomized (52 G+C, 51 TC) and 100 received treatment (51 G+C, 49 TC; Figure 1).
Baseline characteristics are summarised in Table 1 and were well balanced between the two
arms in terms of age, performance status, prior therapy, and ethnicity. More patients
randomized to the G+C arm had PPC compared to those randomized to TC (10 vs. 0). Most
subjects were white, with a median age of 62 years, and all received prior platinum-based
therapy (Table 1). Of the patients randomized to TC, 11 received weekly paclitaxel, 15
received liposomal doxorubicin, 20 received topotecan, and 3 received gemcitabine. Patients
in the G+C arm received more treatment cycles than subjects in the TC arm (median of 4.0
vs. 2.0 cycles, respectively), with 59% of subjects in the G+C arm receiving at least 3 cycles
of treatment and 37% receiving at least 6 cycles of treatment vs. 47% and 31% of subjects in
the TC arm, respectively. Fifty-five percent of patients from the TC arm crossed over to G+C
arm following progression (Figure 1). Disease progression was the most common reason for
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discontinuing treatment (~80% of patients in each group; Figure 1). The most common
TEAEs occurring in more than 5% of the trial population are reported in Table 2. AE
frequencies between the two arms were similar, but neutropenia, diarrhea, nausea and
vomiting were more common in the G+C arm (Tables 2 and 3).

Author Manuscript

The median duration of PFS in the G+C arm was 16.2 weeks compared to 9.1 weeks in TC
arm (P=0.07; Figure 2A and Table 4). The 6-month PFS rate was 37% in the G+C arm (95%
CI, [0.24; 0.50]) compared to 11% in the TC arm (95% CI, [0.04; 0.22]; p=0.003) and did
not meet the pre-specified criterion for superiority (HR 0.686, 95% CI, [0.456; 1.030];
Figure 2 and Table 4). There was no difference between the two arms in OS (43 and 40
weeks in the G+C and TC arms, respectively; Figure 2B and Table 4), OS survival rate at 6
months (0.72 and 0.67 in the G+C and TC arms, respectively; Table 4), overall response rate
(ORR; 16% and 8% in the G+C and TC arms, respectively; Table 4), or clinical benefit
response by RECIST v1.1 or CA-125 (Table 4, Supplementary Table S2). Twenty-seven
patients from the TC arm crossed over post-progression into the G+C arm and received a
median of 3 cycles (14 subjects received ≥3 cycles and 5 subjects received ≥6 cycles) with a
CA-125 response being confirmed in 6 of 21 evaluable subjects (29%). Patient disposition
and outcomes are included in Supplementary Table S3.
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To determine the biological activity of the G+C regimen, LINE1 methylation was assessed
in PBMCs from 48 patients randomized to the G+C arm. Similar to the first stage of this
trial (17), LINE1 hypomethylation approximated 20% (C1D8 vs. C1D1; range +15% to
−55%; Supplementary Figure S1A) (17). In 15 patients who continued treatment beyond 2
cycles and for whom PBMCs were available, LINE1 hypomethylation observed during
Cycle 1 was maintained or increased during subsequent cycles (Supplementary Figure S1B),
indicating that G+C maintains its biological effects throughout treatment. Correlation
between clinical response and pharmacodynamic effects as measured by LINE-1
hypomethylation in PBMCs was not observed. Promoter methylation of selected genes
representing TSGs (23-24) or tumor antigens known to be methylated in OC (25-26) was
measured in bisulfite-converted DNA obtained from paired tumor biopsies on C1D1 and
C2D8 (n = 8 paired specimens). Treatment-induced hypomethylation of MAGE-A2 and
MAGE-A3 promoters in tumor DNA was significant (Supplementary Figure S1C). A nonsignificant decrease in promoter CpG methylation was also observed for LINE-1 and for the
tumor antigens NY-ESO-1 and MAGE-A11, but not for the TSGs RASSF1A, MLH1 and
BRCA1 (data not shown) or for the differentiation associated gene HOXA11. Taken
together, these results provide evidence that G+C treatment exerts in vivo hypomethylating
activity detectable in PBMCs and tumors.

Author Manuscript

DISCUSSION
This is the first randomized study comparing a regimen of G+C to standard of care
chemotherapy for recurrent platinum-resistant OC. Although the 6-month PFS rate was
higher in the G+C arm than the TC arm, the study did not meet its primary endpoint in this
heavily pre-treated population. These results are comparable with previous single-arm phase
2 studies using an epigenetic priming with decitabine (13-14) or 5-azacitadine (15) prior to
carboplatin. Those trials used repetitive low doses of DNMTIs, which is similar to the
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strategy employed with this class of HMAs in hematological malignancies (27-28). The
repetitive administration of the HMA increases drug exposure of cells undergoing S-phase
and incorporation of the nucleoside analogue into the replicating DNA, trapping DNMTs
and inhibiting de novo methylation.

Author Manuscript

In contrast, a previous trial conducted by the Scottish Gynecological Trials Group that used
bolus administration of decitabine on Day 1 prior to administration of carboplatin a week
later was prematurely closed due to high hematological toxicity and indicated lower efficacy
of the combination regimen compared to carboplatin alone (29). This trial reported reduction
in efficacy with the addition of decitabine to patients with partially platinum sensitive
recurrence when given in conjunction with carboplatin (29). Whether the difference in
administration (bolus vs. low-dose repetitive administration) was solely responsible for the
differences in levels of clinical activity remains unknown. The clinical efficacy differences
with this trial may be attributable to the Scottish trial’s inclusion of less heavily pre-treated
subjects who retained partial platinum sensitivity. Since increased DNA methylation is
observed in advanced bladder cancer, colon cancer, cholangiocarcinoma, and germ cell
tumors (30), DNMTI-induced sensitization to platinum or to chemotherapy is also explored
in these settings with early promising results having been reported recently in colon cancer
(31).
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The G+C regimen had myelosuppression as the main toxicity. Prolonged neutropenia
required growth factor support in >80% of the patient population to maintain the intended
every-4-week administration of the combination. However, infections were rare and no
episodes of neutropenic sepsis were recorded. Hypersensitivity and other adverse infusion
reactions were observed in 9 (18%) and 8 (15%) patients in the G+C arm compared with 6%
in the TC arm in this trial, which is concordant with similar observations from prior trials of
DNMTIs and carboplatin (13, 29). This is most likely due to increased exposure to platinum
therapy in the experimental arm, but it is also possible HMA treatment may augment type II
allergic reactions.
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The study has few limitations. While all patients in this trial had platinum-resistant disease,
platinum-refractory disease was excluded. Given that carboplatin was not included among
the potential control regimens, and could conceivably induce clinical benefit in selected
patients, this trial cannot exclude the activity of single-agent carboplatin in this population.
Additionally, topotecan administration in the TC arm followed a weekly administration
schedule. While this schedule was favored among treating oncologists due to its favorable
toxicity profile and early reports of activity (32), the regimen was subsequently shown to
induce a decreased response rate compared to the schedule using daily administration for 5
days, although OS was not affected (33). Chemotherapy with bevacizumab became FDAapproved and an accepted standard for patients with platinum resistant OC after results of
Aurelia trial were reported (34), which occurred after the inception of this protocol. Of note
is that prior therapy with bevacizumab was not excluded, and 33 patients enrolled in this trial
had received bevacizumab. The shorter median PFS observed in the control group of this
study (~2 months) compared to the Aurelia trial (3.4 months; 34) reflects a more heavily
pre-treated group patients included here (mean of 3-4 prior regimens) for whom limited
treatment options currently exist.
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High-quality nucleic acids were extracted from tumor biopsies from 40 subjects at baseline
and from 8 patients after two cycles of G+C. The precise mechanism by which G+C induces
anti-tumor responses remains unknown. Our tissue- and cell-based analyses showed a
number of genes and pathways involved in DNA repair and response to chemotherapy (e.g.,
DOK2, miR193a, 14-3-3σ, RASSF1A) are silenced through promoter methylation and reexpressed after guadecitabine treatment (35). Using overexpression or knock-down
strategies, we have shown some of these pathways restore platinum sensitivity in OC cell
lines and xenografts (10, 35). It is likely that not one gene, but a more global genomic
program is reactivated in response to DNA hypomethylation, allowing tumor cells to
undergo apoptosis in response to chemotherapy. Since preclinical models show that
guadecitabine selectively eliminates chemotherapy-resistant OC stem cells (11) by inducing
a cellular differentiation program, the G+C regimen may exert anti-tumor activity through
multiple mechanisms. The low number of post-treatment biopsies collected in the trial limits
the strength of the conclusions we can draw regarding the mechanisms elicited by this HMA
in vivo.
This randomized trial demonstrated that epigenetic priming in combination with carboplatin
did not increase PFS compared to standard chemotherapy, but improved 6-month PFS in
platinum-resistant OC. Although these results do not support development of this strategy
for an unselected population, they suggest a subgroup of patients might have benefitted from
G+C treatment. Future studies should focus on developing predictive markers to enrich a
patient population more likely to benefit from the use of HMAs.
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TRANSLATIONAL RELEVANCE
Although women with ovarian cancer (OC) initially respond to platinum-based
chemotherapy, platinum-resistance commonly develops, leading to fatal outcomes. We
set out to determine if epigenetic priming with a hypomethylating agent (HMA) prior to
carboplatin improved progression-free survival (PFS) in platinum-resistant OC when
compared with physician’s choice chemotherapy in a randomized phase 2 trial. The
median PFS and overall survival were not different, but the 6-month PFS rate was higher
in the experimental group. Myelosuppression was the main toxicity observed with the
experimental regimen and hypomethylating activity was measurable in PBMCs. Further
development of the strategy will require identification of predictive biomarkers for
patient selection.
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Figure 1. Disposition of subjects in the trial.

AUC indicates the target area under the concentration-versus-time curve.
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Figure 2. Survival of subjects assigned to G+C arm versus TC arm.

A: Kaplan-Meier estimates of progression-free survival with the G+C treatment and TC
regimens. B: Kaplan-Meier estimates of overall survival with the G+C treatment and TC
regimens. For subjects in the TC group who crossed over to receive G+C, OS time was
censored at the crossover time point.
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Table 1.

Author Manuscript

Patient characteristics
G+C
(n=51)

TC
(n=49)

TC crossover
(TC to G+C)
(n=27)

62.0

62.1

63.7

Demographics and Baseline Characteristics
Age (y)
Mean
SD

9.2

9.6

8.8

Median

62.1

62.2

64.1

40.6-88.4

38.9-78.5

49.6-78.5

Asian

5 (10)

6 (12)

3 (11)

Black or African American

2 (4)

2 (4)

2 (7)

Min-max
Race

Native Hawaiian or Other Pacific Islander

Author Manuscript

0

1 (2)

0

White

43 (84)

40 (82)

22 (81)

Other

1 (2)

1 (2)

1 (4)

Ethnicity
Hispanic or Latino

2 (4)

3 (6)

3 (11)

49 (96)

46 (94)

24 (89)

HGSOC

39 (76)

47 (96)

High-grade serous PPC

10 (20)

0

2 (4)

2 (4)

Measurable disease (RECIST)

44 (86)

46 (94)

Detectable disease (GCIC)

7 (14)

3 (6)

0

18 (35)

23 (47)

13 (48)

1

33 (65)

25 (51)

14 (52)

2

0

1 (2)

0

1-2

11 (22)

14 (29)

7 (26)

3-4

21 (41)

16 (33)

8 (30)

≥5

19 (37)

19 (39)

12 (44)

17 (33)

14 (28.6)

Mean

288

378

SD

245

290

Not Hispanic or Latino
Diagnosis, n (%)

High-grade serous FT cancer
Disease Assessment, n (%)

Author Manuscript

ECOG Performance Status, n (%)

Number of Prior Regimens, n (%)

Number of subjects with prior bevacizumab

a

Time since last platinum therapy (days)

Author Manuscript

a

Includes cisplatin, carboplatin, or oxaliplatin
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Author Manuscript

Treatment-related AEs occurring in ≥10% of patients in either arm
G+C
(n=51)

TC
(n=49)

ANY RELATED EVENT

47 (92)

43 (88)

b

36 (71)

16 (33)

Nausea

28 (55)

21 (43)

Fatigue

24 (47)

21 (43)

20 (39)

0

18 (35)

8 (16)

Anemia

16 (31)

23 (47)

Leukopenia

16 (31)

10 (20)

Hypomagnesaemia

12 (24)

4 (8)

Thrombocytopenia

11 (22)

12 (24)

Constipation

10 (20)

9 (18)

Decreased appetite

10 (20)

8 (16)

Stomatitis

10 (20)

12 (24)

9 (18)

3 (6)

Arthralgia

7 (14)

5 (10)

Diarrhea

7 (14)

5 (10)

Headache

6 (12)

1 (2)

Alopecia

5 (10)

7 (14)

a

AE

Neutropenia

b,d

Injection site reaction

c

Vomiting

Author Manuscript

d

Drug hypersensitivity

a

P > 0.050 unless otherwise stated

Author Manuscript

b

P < 0.001

c

P = 0.040

d

Due to variability in reporting terms, events of injection site reaction (typically attributed to guadecitabine SQ injection), drug hypersensitivity
(typically attributed to carboplatin), anaphylactic reaction, adverse drug reaction, and infusion related reaction were analyzed as a group term and
were observed in 32 subjects (33%) who received the G+C treatment.
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Table 3.

Author Manuscript

AEs of CTCAE grade 3 or higher occurring in >1 patient in either arm
TC
(n=49)

48 (94)

31 (63)

b

34 (67)

9 (18)

c

13 (25)

4 (8)

Anaemia

9 (18)

8 (16)

Bowel obstruction

12 (24)

8 (16)

Fatigue

6 (12)

6 (12)

Diarrhea

3 (6)

0

Thrombocytopenia

3 (6)

4 (8)

Vomiting

3 (6)

4 (8)

Abdominal distension

2 (4)

1 (2)

Abdominal pain

2 (4)

2 (4)

Ascites

2 (4)

2 (4)

Hypertension

2 (4)

2 (4)

Hypokalemia

2 (4)

3 (6)

Nausea

2 (4)

4 (8)

Pyrexia

2 (4)

0

Decreased appetite

1 (2)

2 (4)

Dehydration

1 (2)

2 (4)

Pulmonary embolism

1 (2)

2 (4)

Pneumonia

0

2 (4)

Sepsis

0

2 (4)

b

ANY GRADE ≥3 EVENTS
Neutropenia
Leukopenia

Author Manuscript
Author Manuscript

G+C
(n=51)

a

AE

a

P > 0.050 unless otherwise stated

b

P < 0.001

c

P = 0.032
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Table 4.

Author Manuscript

Survival and response

a
G+C
(n=51)

TC
(n=49)

16.3 [9, 24.1]

9.1 [7.4, 15]

PFS rate at 6 months, median [95% CI]

0.37 [0.24,0.50]

0.11 [0.04,0.22]

OS, (TC censored) median in weeks [95% CI]

47.3 [33, 59.3]

31.5 [20.7, 53.1]

0.72 [0.58, 0.83]

0.67 [0.47, 0.80]

8 (16)

4 (8)

[7.0, 28.6]

[2.3, 19.6]

21 (41)

14 (29)

[27.6, 55.8]

[16.6, 43.3]

21

14

26.6 [21, 34.4]

24.7 [17.3, 38.1]

42

41

p-value

Survival
PFS, median in weeks [95% CI]

OS rate at 6 months, (TC censored) median [95% CI]

b

0.0654

c

0.0027

b

0.5852

c

0.5629

Response Rate
ORR (CR/FR+PR), n (%)

Author Manuscript

[95% CI]
CBR (CR/FR+PR+stable disease), n (%)
[95% CI]

d

0.3580

d

0.2130

Duration of Response in Responders
Number of responders
Median duration, weeks [95% CI]
CA-125 Response, n
Number (%) of subjects with ≥50% reduction
Median best % change from baseline (min, max)

15 (36)

13 (32)

−43 (−98, 154)

−10 (−98, 248)

Author Manuscript

AE=adverse event; CBR= clinical benefit rate; CI=confidence interval; CR=complete response; CRc=composite complete response; FR=full
response per GCIC criteria; ORR=objective response rate; OS=overall survival; PFS=progression free survival; PR=partial response. Subjects were
primarily assessed by RECIST, but in the event that an enrolled subject with measurable disease was not evaluable by RECIST (e.g. inadequate
follow up scan) and had evaluable data by GCIC CA-125 criteria, the latter was used. From the G group, there were 5 PR by RECIST of 44
evaluable and 3 PR/FR by GCIC of 7 subjects with detectable disease. From the TC group there were 4 PR by RECIST of 44 evaluable and 0
PR/FR of 3 evaluable by GCIC CA-125 criteria.

a

Guadecitabine 30 mg/m2 on Days 1-5 and carboplatin AUC 4 on Day 8 of 28-day treatment cycles.

b

Log-rank test for the overall PFS or OS curve.

c

Chi-square test.

d

Fisher’s exact test.
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